China Approves Five COVID-19 Antigen Kits for Self-Testing, Marks Official Market Launch of New Test Kits

New Advanced Immunoassay Technology Raises Excitement in the Medical Field

Scientists and medical professionals worldwide are constantly looking for ways to improve diagnostic procedures and treatments for diseases. One of the latest advancements in this field is the development of Fia Immunoassay technology. This revolutionary approach to diagnosing diseases promises to revolutionize the world of medicine. The Fia Immunoassay technology is a recently launched and unique diagnostic approach that uses biochemistry and molecular biology techniques to detect biomarkers present in body fluids or tissue samples. The technology combines state-of-the-art hardware and software to provide accurate and reliable results in real-time. The need for an efficient diagnostic approach in medicine has been growing rapidly in recent years. Diseases such as cancer, diabetes, and heart diseases are prevalent worldwide, resulting in over 600,000 deaths each year. The Fia Immunoassay technology is a much-needed step towards improving the diagnostic accuracy and treatment of these diseases. The technology makes use of immunoassay chemistry, which utilizes the specific interaction between antigen and antibody molecules to quantify the presence of biomarkers in biological samples. In simple terms, it works by capturing the target analyte with an antibody that is immobilized onto the surface of beads or particles. The captured analyte is then detected by a signal-generating system, which gives the readout.Fia Immunoassay technology is unique in many ways. Unlike traditional diagnostic tests, which rely on multiple steps, the Fia Immunoassay technology combines all of these steps into a single system. This means that samples can be analyzed quickly and efficiently, thereby increasing the throughput and accuracy of diagnosis. The technology also allows for the detection of multiple biomarkers in a single assay, which is useful in the diagnosis of complex diseases such as cancer. One company that has embraced the Fia Immunoassay technology is Rapid Biosensor Systems. The company is based in Ireland and has developed a range of diagnostic platforms that utilize the Fia Immunoassay technology. The Rapid Biosensor Systems Fia Immunoassay platform includes a handheld reader that can be used by healthcare professionals at the point of care. The platform is designed to provide tests for a wide range of diseases, including infectious diseases, cancer, cardiac markers, and biomarkers of inflammation. The Rapid Biosensor Systems Fia Immunoassay platform is already being used in clinics and hospitals worldwide, with promising results. In a recent study, the platform was used to diagnose cancer in patients using a blood sample. The platform was able to detect tumor-specific antigens with high sensitivity and specificity, indicating its potential as a diagnostic tool in oncology. The technology is also being used in the diagnosis of infectious diseases such as COVID-19. The Rapid Biosensor Systems Fia Immunoassay COVID-19 antigen test has been granted Emergency Use Authorization by the FDA and has been used worldwide to diagnose COVID-19. The Fia Immunoassay technology has the potential to revolutionize the world of healthcare. Its ability to provide accurate and real-time diagnosis has the potential to save lives and improve the quality of life of patients. The technology is also expected to play a significant role in drug discovery and clinical research. It allows for the rapid and efficient detection of biomolecules, making it an essential tool for the development of new drugs and therapies. In conclusion, the Fia Immunoassay technology is a revolutionary approach to diagnosing diseases. Its ability to provide accurate and real-time results, coupled with its simplicity and efficiency, makes it a game-changer in the world of healthcare. Rapid Biosensor Systems is one company that is leading the charge in harnessing the potential of Fia Immunoassay technology. Its platforms have already been used in the diagnosis of various diseases, and the company continues to innovate and develop new applications for the technology. With the Fia Immunoassay technology, the future of healthcare looks brighter than ever before.

Humans Benefit from Advanced Timp1 Elisa Kits: Latest News

Scientists at a biotechnology company have developed a new tool to detect human TIMP1, a protein that plays a crucial role in regulating tissue growth and repair. The tool, known as a Human TIMP1 ELISA Kit, is the first of its kind and will enable researchers and clinicians to study the protein's function in depth.Human TIMP1 is a member of a family of proteins called tissue inhibitors of metalloproteinases (TIMPs), which regulate the activity of enzymes called matrix metalloproteinases (MMPs). These enzymes play a crucial role in remodeling tissues during development and wound healing, but when they are overactive, they can contribute to many diseases, including cancer and arthritis.By measuring the levels of TIMP1 in blood or other bodily fluids, researchers can gain insights into MMP activity and tissue remodeling in various diseases. However, existing methods for detecting TIMP1 are time-consuming and require large sample volumes. The new Human TIMP1 ELISA Kit, developed by the biotechnology company, overcomes these limitations by providing a highly sensitive and specific assay for TIMP1 in small sample volumes."We are excited to introduce this new tool to the research community," said a spokesperson from the company. "The Human TIMP1 ELISA Kit will enable researchers to better understand the role of TIMP1 in various diseases and potentially develop new therapies that target this protein."The spokesperson explains that the kit is designed for use in a wide range of applications, including basic research, drug development, and clinical diagnosis. The company also offers technical support and customized services, such as assay validation and optimization, to help researchers achieve reliable and accurate results.The Human TIMP1 ELISA Kit is based on the enzyme-linked immunosorbent assay (ELISA) technology, which uses antibodies to capture and detect specific proteins in a sample. To use the kit, researchers simply add a small amount of the sample to a well coated with anti-TIMP1 antibodies. If TIMP1 is present in the sample, it will bind to the antibodies and form a complex. After washing away any unbound materials, a second antibody labeled with an enzyme is added to the well. This antibody binds to the complex, allowing the enzyme to convert a substrate into a detectable signal, typically a color change or a fluorescence.The ELISA process is quick and easy, taking only a few hours to complete. The kit is designed to be user-friendly, with step-by-step instructions and all necessary reagents provided. Researchers can analyze multiple samples in parallel, making the kit suitable for high-throughput analyses.The spokesperson emphasizes the importance of TIMP1 in health and disease and the potential of the Human TIMP1 ELISA Kit to advance TIMP1-related research. "TIMP1 is a key regulator of tissue remodeling and is involved in many physiological and pathological processes," they said. "This kit will enable researchers to better understand the complexities of these processes and potentially identify new therapeutic targets."The Human TIMP1 ELISA Kit is now available for purchase directly from the biotechnology company's website. The spokesperson encourages interested researchers to contact the company for more information and assistance with using the kit.Overall, the Human TIMP1 ELISA Kit represents a significant advancement in the study of TIMP1 and its role in health and disease. By providing a fast, accurate, and sensitive assay for TIMP1, the kit will enable researchers and clinicians to gain new insights into tissue remodeling and potentially develop new therapies for many diseases. The kit is also an example of the ongoing efforts by biotechnology companies to develop innovative tools and technologies for biomedical research.

As at-home rapid tests replace PCRs, better guidance needed for COVID-19 guidelines

Title: Simplifying Public Health Guidance Essential as At-Home Rapid Tests Rise in PopularityIntroduction:As the world continues to grapple with the COVID-19 pandemic, there has been a shift towards utilizing at-home rapid tests as a means to control the spread of the virus. However, it is increasingly evident that the complex and often poorly communicated public health guidelines surrounding COVID-19 have proven challenging for both individuals and healthcare professionals. In this article, we explore the need for clearer, simplified guidance in the face of the growing popularity of at-home rapid tests.Blaming People vs. Addressing Communication Gaps:Throughout the pandemic, there has been a tendency to place blame on individuals for non-compliance, labeling them as ignorant or selfish. However, the reality is that individuals often struggle to navigate the convoluted and contradictory public health guidelines. To effectively manage the ongoing crisis and establish a sense of collective responsibility, it is crucial to recognize the need for clearer and more accessible communication.The Rise of At-Home Rapid Tests:As at-home rapid tests gain traction, these user-friendly and easily accessible tools have the potential to revolutionize COVID-19 testing. Consumers can now perform the tests in the comfort of their own homes, avoiding long waiting times and reducing potential exposure to the virus at testing centers. With the demand for rapid tests increasing, it is vital to ensure that the guidance surrounding their use is clear, concise, and comprehensible even to those outside the medical field.The Complexities of Public Health Guidelines:The primary obstacle in effective compliance with public health guidelines lies in their complexity. For months, the public has been bombarded with intricate instructions that are at times contradictory or inconsistent. These guidelines often fail to consider the limitations and difficulties faced by individuals attempting to make informed decisions about their health and the health of those around them.A Call for Simplified Guidelines:To truly tackle the COVID-19 pandemic and ensure compliance, it is necessary to simplify the messaging surrounding public health guidelines. Clear, concise, and consistent instructions must replace the current overwhelming jumble of information. By providing easy-to-understand guidance, individuals will be better equipped to make informed decisions about testing, isolation, and preventive measures.The Role of Healthcare Professionals:Medical professionals also face challenges when comprehending and communicating the rapidly evolving information surrounding COVID-19. Simplifying public health guidelines would not only benefit the general public but also assist healthcare professionals in providing accurate and consistent information. Alignment between public health authorities and medical experts is vital in ensuring effective communication and understanding of guidelines.Collaboration with Rapid Test Manufacturers:To enhance clarity and understanding, collaboration between public health authorities, medical professionals, and rapid test manufacturers is crucial. By integrating the expertise of healthcare providers and manufacturers during the development of at-home rapid tests, comprehensive and user-friendly instructions can be provided. This would empower individuals to take control of their health while minimizing the risk of misinterpretation and non-compliance.Conclusion:If we are to successfully coexist with COVID-19, it is imperative that public health guidelines and recommendations be simplified and well-communicated. By shifting the focus from blaming individuals to addressing communication gaps, we can ensure that at-home rapid tests are utilized effectively in controlling the spread of the virus. Collaboration between key stakeholders, including healthcare professionals and manufacturers, will pave the way for comprehensive and understandable guidance, enabling individuals to make informed decisions regarding their health and the welfare of their communities.

Global EQA/Proficiency Testing Scheme Monitors Performance of Specialized Immunoassay Parameters

RIQAS Immunoassay Speciality 1 EQA Programme: Ensuring Accurate Performance of Immunoassay ParametersImmunoassays are vital tests that are used to measure the concentration of different analytes such as hormones, proteins, drugs, and infectious agents in clinical and research laboratories. These tests play a significant role in the diagnosis, management, and monitoring of various medical conditions. However, the complexity and diversity of immunoassay techniques make it challenging to ensure the accuracy and reliability of test results. That is where the RIQAS Immunoassay Speciality 1 EQA programme comes in.What is RIQAS Immunoassay Speciality 1 EQA?RIQAS (Randox International Quality Assessment Scheme) is a world-renowned external quality assessment (EQA) scheme that offers comprehensive proficiency testing programmes to enhance the quality and proficiency of clinical laboratories worldwide. The RIQAS Immunoassay Speciality 1 EQA scheme is designed to monitor the performance of ten complex and specialised immunoassay parameters, including:1. Adrenocorticotropic hormone (ACTH)2. Anti-Thyroglobulin3. Anti-TSH Receptor4. Cortisol5. Insulin6. Intact Parathyroid Hormone (iPTH)7. Prostate Specific Antigen (PSA)8. 25-Hydroxy Vitamin D (25-OH Vitamin D)9. 1,25-Dihydroxy Vitamin D (1,25(OH)2 Vitamin D)10. TestosteroneWhy is EQA important for Immunoassay Testing?EQA is an essential tool for assessing the performance of clinical laboratories and ensuring the accuracy and reliability of test results. The use of EQA programmes enables laboratories to benchmark their performance against other laboratories worldwide and identify areas of improvement in their testing processes. Immunoassays are particularly sensitive to inter-laboratory variation and require regular EQA to ensure clinical accuracy.Benefits of RIQAS Immunoassay Speciality 1 EQAThe RIQAS Immunoassay Speciality 1 EQA programme offers a range of benefits to participating laboratories, including:1. Quality Control - The programme provides an objective assessment of laboratory performance and identifies potential problems before they affect test results.2. Cost-Effective - By participating in the RIQAS Immunoassay Speciality 1 EQA programme, laboratories can save time and money by reducing the need for in-house quality control materials.3. Continuous Improvement - Through regular participation in the RIQAS Immunoassay Speciality 1 EQA programme, laboratories can improve their testing processes and ensure better patient outcomes.4. International Benchmarking - The programme allows laboratories to compare their performance against other laboratories worldwide and identify areas of improvement.5. Accreditation - Participating in an EQA scheme such as RIQAS Immunoassay Speciality 1 EQA can help laboratories meet regulatory and accreditation requirements.ConclusionThe RIQAS Immunoassay Speciality 1 EQA programme provides a comprehensive external quality assessment scheme for laboratories using specialised immunoassay testing. By providing objective, continuous, and cost-effective QC, the RIQAS Immunoassay Speciality 1 EQA programme enables laboratories to consistently produce reliable and accurate test results. The benefits of participating in the RIQAS Immunoassay Speciality 1 EQA programme extend beyond the laboratory, providing improved patient outcomes, meeting regulatory requirements, and international benchmarking.

The BD Veritor System for Rapid Detection of Group A Strep is a revolutionary medical tool that employs immunoassay technology to provide quick and accurate results for the detection of Group A Streptococcus antigen. This rapid chromatographic immunoassay can be conducted on a throat swab sample taken from symptomatic patients. The BD Veritor System Reader is used to interpret and analyze the results, rendering an efficient diagnostic tool that can benefit both medical professionals and patients.Immunoassay Test Hindi is the procedure that the BD Veritor System employs to rapidly detect Group A Streptococcus antigen. The immunoassay method is based on the principle of antigen-antibody interaction, where the antigen is the protein on the surface of the bacteria that causes Group A Streptococcal infection and the antibody is the specific protein that recognizes and binds to the antigen. When the throat swab sample is applied to the BD Veritor System cartridge, the device's sensors detect any Group A Streptococcus antigen present in the specimen, which in turn triggers a chemical reaction.This chemical reaction causes a distinctive color change that is discernable through visual interpretation or through the use of the BD Veritor System Reader. The Reader precisely quantifies and analyzes the results in minutes and generates an accurate readout and diagnosis. This innovative technology reduces the waiting time for diagnostic results, enabling medical professionals to diagnose and treat infected patients more rapidly, which is vital, especially in cases of Group A Streptococcal infections.The BD Veritor System for Rapid Detection of Group A Strep is a simple and user-friendly diagnostic tool that can be utilized in numerous medical settings, such as hospitals, clinics, and physician's offices. This robust system has been clinically proven for its precise and reliable results, rendering it a highly useful tool for detecting Group A Streptococcal antigen. The immunoassay-based test is easy to administer, and the results can be interpreted even by non-medical personnel with the right training.In conclusion, the BD Veritor System is a remarkable medical tool that utilizes the latest immunoassay technology to detect Group A Streptococcus antigen rapidly. The immunoassay technology accurately detects the antigen and its reaction with the specific antibody, allowing medical professionals to provide a quick and precise diagnosis, which is important for positive patient outcomes. The use of the BD Veritor System can aid in controlling the spread of Group A Streptococcal infections and may even save lives. Therefore, it is definitely a medical tool worth investing in for quick and reliable testing of Group A Streptococcus antigen.

Latest Updates and News on Antigens: Videos and Photos Available

In recent years, the study of antigens has become increasingly important in the medical field. Antigens are a type of molecule that trigger an immune response in the body. This response can range from mild, such as a rash or fever, to severe, such as anaphylaxis or death. Antigens come in many forms, including bacteria, viruses, pollen, and even cancer cells.One company that has been at the forefront of developing new antigen-based therapies is company. Since its founding in 2005, company has been focused on developing innovative medical treatments using antigens. The company has a particular focus on developing immunotherapies for cancer and autoimmune diseases.One of company's most promising treatments is a cancer vaccine called vaccine name. The vaccine works by stimulating the body's immune system to target cancer cells. This is done by injecting the patient with a unique combination of antigens that are found on the surface of cancer cells. By introducing these antigens into the patient's body, the immune system is trained to recognize and attack cancer cells.Clinical trials of vaccine name have shown promising results. In one trial, patients with advanced melanoma who received the vaccine had a significantly longer overall survival rate than those who did not receive the vaccine. This has led to optimism that vaccine name could become a valuable tool in the fight against cancer.In addition to cancer immunotherapy, company is also developing treatments for autoimmune diseases using antigens. One of the company's lead candidates is a drug for multiple sclerosis called drug name. This drug works by targeting specific antigens that are believed to play a role in the development of the disease. By blocking these antigens, drug name could potentially reduce the severity of symptoms and slow the progression of the disease.company is not the only company working on antigen-based therapies, but it is certainly one of the most innovative. As the medical community continues to learn more about antigens and their role in disease, it is likely that we will see many more antigen-based treatments in the future. These treatments have the potential to transform the way we treat some of the most complex and difficult-to-treat diseases, and company is well positioned to be at the forefront of this revolution.

New range of PCR Detection Kits for Chikungunya, Dengue, Japanese Encephalitis, Treponema Pallidum, Zika and Multiplex Viral Infections now available from CerTest.

Abacus dx, a leading provider of medical diagnostic solutions, has announced the launch of the VIASURE range of molecular PCR detection kits, now available from CerTest. The new range includes solutions for several viral and bacterial diseases, including Chikungunya, Dengue, Japanese Encephalitis, Syphilis, and Zika.VIASURE PCR detection kits are CE-IVD certified, providing reliable and accurate results in a short amount of time. These kits use real-time PCR technology to detect specific virus and bacterial DNA or RNA sequences in patient samples, making them an effective solution for diagnosing infectious diseases.One of the key benefits of VIASURE PCR detection kits is their ability to perform multiplex testing, allowing the detection of multiple pathogens in a single sample. This feature makes VIASURE kits particularly useful in areas where multiple infectious diseases coexist, as it can reduce the cost and time required for testing.The VIASURE Syphilis PCR kit, which detects the presence of Treponema pallidum, the bacterium responsible for Syphilis, is a particularly noteworthy addition to the range. Syphilis is a sexually transmitted infection that affects millions of people worldwide each year. If left untreated, Syphilis can lead to severe health problems, including blindness, dementia, and even death.The VIASURE Syphilis PCR kit is one of the first commercial PCR-based detection kits for Syphilis to receive CE-IVD certification. Its high sensitivity and specificity make it an effective tool for diagnosing Syphilis, especially during early stages where traditional screening tests may not yet detect the infection.The new range of VIASURE PCR detection kits is an excellent addition to Abacus dx's existing portfolio of diagnostic solutions. According to the company's Managing Director, Tony Horder, the addition of VIASURE to our product range demonstrates our commitment to providing the most advanced molecular diagnostic solutions to healthcare professionals across Australia and New Zealand.CerTest, the distributor of VIASURE PCR detection kits, is an established provider of diagnostic products in Europe, offering a range of in vitro diagnostic solutions for infectious diseases, genetics, and oncology. The partnership between Abacus dx and CerTest marks an important step in expanding the availability of advanced molecular diagnostic solutions in the Asia-Pacific region.In conclusion, the launch of the new VIASURE range of molecular PCR detection kits provides healthcare professionals with reliable and accurate diagnostic solutions for significant infectious diseases. With their real-time PCR technology, multiplex testing capabilities, and high sensitivity and specificity, these kits have the potential to improve patient outcomes significantly. The partnership between Abacus dx and CerTest is an essential development, paving the way for the introduction of advanced molecular diagnostic solutions in the Asia-Pacific region.

Quantitative Measurement of Antigens with Enzyme Immunoassay (EIA)

Direct Enzyme Immunoassay: A Powerful Tool for Quantitative AnalysisWhen it comes to measuring the quantity of any substance that possesses the properties of antigens, immunogenic or non-immunogenic (haptens), direct enzyme immunoassay (EIA) is an effective quantitative analytical technique. This technique is widely used in the fields of medical diagnostics, environmental monitoring, and food safety testing.In a direct enzyme immunoassay, a purified antigen is required. The assay can detect the antigen directly, without any additional steps. The antigen-specific antibody is coated on a solid support, such as a microtiter plate, referred to as the capture antibody. The antigen is then added along with an enzyme-conjugated antibody specific to the captured antigen. Following an incubation period, any unbound reagents are washed off, and a substrate is added to allow for the detection and quantification of the enzymatic reaction. The extent of the reaction is directly proportional to the amount of antigen present in the sample.Direct enzyme immunoassays offer numerous advantages over other quantitative analytical techniques. Firstly, they are highly sensitive and specific, able to detect very low levels of analyte within a sample. This is especially important in medical diagnostics, where early detection of specific biomarkers can be critical to a positive patient outcome. Secondly, direct enzyme immunoassays are relatively easy to perform, and can be adapted to detect a wide variety of analytes. Finally, direct enzyme immunoassays can be performed in a high-throughput manner, making them ideal for use in industrial or research labs that require large numbers of analyses to be performed quickly and efficiently.Direct enzyme immunoassays have been used in a variety of applications. In medical diagnostics, they are used to detect the presence of disease-related biomarkers, such as cardiac troponin, prostate-specific antigen, and thyroid-stimulating hormone. In environmental monitoring, direct enzyme immunoassays have been used to detect and quantify pollutants such as pesticides, herbicides, and heavy metals. And in food safety testing, direct enzyme immunoassays have been used to detect food allergens, bacterial pathogens, and veterinary drug residues.In conclusion, direct enzyme immunoassay is a powerful analytical tool that has wide applicability in various fields, including medical diagnostics, environmental monitoring, and food safety testing. It offers high sensitivity and specificity, ease of use, and high-throughput capability, making it an ideal choice for analytical laboratories that require speedy, accurate, and reliable quantitative analysis. As technology continues to advance, it is likely that direct enzyme immunoassay will continue to be a valuable and vital tool for analytical chemistry.

What is Immunoassay? Definition and Explanation in the Medical Field

A Look Into Quantitative ImmunoassayMedical testing has seen vast improvements over the years and currently, one of the most effective ways to diagnose various diseases is through immunoassay. Immunoassay is a procedure that determines the presence and quantity of molecules in a solution such as antibodies, hormones, and other proteins by using an antibody or immunoglobulin binding method. This process has become widely popular and has evolved to become quantitative immunoassay.Quantitative immunoassay is a testing method that measures the amount of a certain substance in a given sample. This testing process has become a critical tool for the diagnosis of many diseases, such as thyroid abnormalities, cancers, and various infectious diseases. It is also used to monitor therapeutic treatments and to determine the efficiency of vaccines in clinical trials.The procedure is simple; it involves the mixing of a known volume of sample with reagents in a testing kit. The reagents in the kit are designed to bind to the specific molecules that are being tested for in the sample. The bond between the reagents and the molecule being tested for results in a measurable signal; this signal is then quantified to give the concentration of the molecule in the sample.There are different types of quantitative immunoassays for measurements. The first of them is the Enzyme-Linked Immunosorbent Assay (ELISA) which uses enzymes to catalyze the reaction and yield a measurable signal. Radioimmunoassay (RIA) is another type of quantitative immunoassay that can detect substances of low concentrations due to the presence of radioactive isotopes within the testing environment.With the advancements in technology and the availability of more specific antibodies, the sensitivity and accuracy of these tests have improved. More so with the development of fully automated immunoassay analyzers that can handle a high volume of samples with faster turnaround times. These advances have made quantitative immunoassays more accessible and practical, with the test being non-invasive, less expensive, and can be performed outside of the laboratory settings.In conclusion, quantitative immunoassay has proven to be an effective, efficient, and reliable means of diagnosing diseases. The availability of automated testing systems means it can be conducted efficiently, and the non-invasive nature of the test makes it more acceptable to patients. As technology continues to evolve, it is likely that more specific molecules will be identified for immunoassay procedures, thereby expanding the scope of this critical diagnostic tool.

Intraoperative PTH Monitoring: Importance and Applications in Calcium Regulation

, Intraoperative PTH Monitoring, Parathyroid Gland, Calcium Regulation, Primary Hyperparathyroidism.Parathyroid hormone (PTH) is a crucial biomarker that physicians use to diagnose and manage patients with parathyroid gland-related disorders. The measurement of PTH in serum or plasma is an important tool for the diagnosis and management of primary hyperparathyroidism.Intraoperative PTH monitoring using PTH immunoassay during parathyroidectomy is a widely accepted technique for monitoring the effectiveness of the procedure. The ultimate goal of surgery is to remove all hyperfunctioning parathyroid tissues, leading to a reduction in serum PTH levels. The PTH immunoassay allows for the rapid measurement of serum PTH levels during surgery and is an excellent tool for determining the success of the surgical procedure.PTH is produced by the parathyroid gland, four small glands located in the neck. Parathyroid hormone plays a vital role in calcium regulation, keeping the level of calcium in the blood constant. When the calcium level in the blood decreases, the parathyroid glands produce more PTH, which increases the amount of calcium released from the bones, increases the absorption of calcium from the intestine, and decreases the excretion of calcium through the kidneys.Primary hyperparathyroidism is the most common endocrine disorder, characterized by overactive parathyroid glands, leading to elevated levels of plasma calcium and PTH concentrations. The excessive PTH production and secretion from the parathyroid gland lead to high levels of calcium in the blood, resulting in various medical complications. The most common complication of primary hyperparathyroidism is kidney stones, followed by bone pain and osteoporosis.Parathyroidectomy is the surgical removal of one or more of the parathyroid glands, which is the only cure of primary hyperparathyroidism. Intraoperative PTH monitoring during parathyroidectomy is a valuable tool for verifying the success of surgery. The PTH immunoassay allows for the rapid measurement of serum PTH levels during the surgical procedure, helping surgeons to ensure that all hyperfunctioning parathyroid glands have been removed.To perform intraoperative PTH monitoring, a baseline PTH level is measured before the surgery. After the removal of a suspected hyperfunctioning gland, the PTH level is again measured at 10-15 minutes and 20-30 minutes after the gland removal. If the PTH level drops by 50% or more from the baseline level, it confirms successful removal of the hyperfunctioning gland.PTH immunoassay is a sensitive and specific laboratory method that measures the PTH concentration in serum or plasma. The immunoassay is a rapid and reliable method for measuring serum PTH levels and is used in the diagnosis and management of primary hyperparathyroidism. The availability of PTH immunoassay has revolutionized the intraoperative PTH monitoring, making it an essential tool to ensure the success of parathyroidectomy surgery.Intraoperative PTH monitoring using PTH immunoassay is an essential tool for verifying the success of parathyroidectomy surgery. The PTH immunoassay allows for the rapid measurement of serum PTH levels during surgery, providing clinicians with rapid feedback on the effectiveness of the procedure. Early detection and successful treatment of primary hyperparathyroidism can prevent long-term complications such as bone density loss and osteoporosis.